Proinsulin peptides for Type 1 Diabetes
AssigneeKing's College London
InventorsMark Peakman, Johan Verhagen, Martin Eichmann
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a peptide that can be used in the therapy or prevention of Type 1 Diabetes (T1D), particularly in a patient with a DR3-DQ2 haplotype, as well as methods of diagnosing or determining treatment efficacy, methods of identifying T1D-relevant antigen drivers, and to methods of identifying subjects as being at high-risk of T1D and patients as being suitable for and/or responsive to T1D treatment.
Claims11
A method of treatment of Type 1 Diabetes (T1 D) comprising administering to a patient with T1 D or a non-diabetic individual identified as being at high-risk of T1 D wherein the patient has a Human Leukocyte Antigen (HLA) DR isotype 3 (DR3)-DQ2 haplotype a pharmaceutically acceptable composition comprising a peptide having at least 90% homology to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4 or SEQ ID NO:
- 5, or a peptide combination thereof, and one or more pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.